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Forecasting future prevalence of type 2 diabetes
mellitus in Syria
Radwan Al Ali1,2*, Fawaz Mzayek1,3, Samer Rastam1,2, Fouad M Fouad1, Martin O’Flaherty4, Simon Capewell4
and Wasim Maziak1,5
Abstract
Background: Type 2 diabetes mellitus (T2DM) is increasingly becoming a major public health problem worldwide.
Estimating the future burden of diabetes is instrumental to guide the public health response to the epidemic. This
study aims to project the prevalence of T2DM among adults in Syria over the period 2003–2022 by applying a
modelling approach to the country’s own data.
Methods: Future prevalence of T2DM in Syria was estimated among adults aged 25 years and older for the period
2003–2022 using the IMPACT Diabetes Model (a discrete-state Markov model).
Results: According to our model, the prevalence of T2DM in Syria is projected to double in the period between
2003 and 2022 (from 10% to 21%). The projected increase in T2DM prevalence is higher in men (148%) than in
women (93%). The increase in prevalence of T2DM is expected to be most marked in people younger than 55 years
especially the 25–34 years age group.
Conclusions: The future projections of T2DM in Syria put it amongst countries with the highest levels of T2DM
worldwide. It is estimated that by 2022 approximately a fifth of the Syrian population aged 25 years and older will
have T2DM.
Background
Type 2 diabetes mellitus (T2DM) is a worldwide public
health problem affecting populations at all levels of so-
cioeconomic development. Diabetes is characterized by
chronic hyperglycemia, and is frequently accompanied
by dyslipidemia, hypertension, and endothelial dysfunc-
tion. Diabetes therefore, is a major risk factor for cardio-
vascular vascular disease [1].
The prevalence of T2DM is increasing worldwide and
has reached alarming levels in many countries around
the world. It is estimated that 366 million people were
affected by diabetes in 2011 globally, and the number is
projected to increase to 552 million in 2030 [2]. Low-
and middle-income countries face the greatest threat of
diabetes, where between 2010 and 2030 a 70% increase
in the number of adults with diabetes is projected to
take place compared to 20% for developed countries [3].
This increase has been linked to population growth and
aging, as well as increasing urbanization, obesity and
physical inactivity [4,5].
Still, many governments and public health planners in
developing countries remain largely unaware of the
current magnitude and future burden of diabetes in their
societies [2]. Projecting future trends in diabetes in devel-
oping counties, therefore, can help in guiding a propor-
tionate public health response to the diabetes epidemic.
Syria is going through many of the changes that can in-
fluence diabetes trends in a negative way. Still, no study to
date has attempted to use available national data to fore-
cast future trends in diabetes in Syria. The paucity of data
sources in Syria prompted the use and adaptation of the
IMPACT Diabetes model that requires fewer data inputs
to project T2DM prevalence among adults in Syria over
the period 2003 to 2022, and to quantify the potential im-
pact of public health interventions aimed to reduce two of
its major risk factors; obesity and smoking.
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Methods
The model
Future diabetes prevalence in Syria was estimated using
the IMPACT Diabetes Model that was developed for this
purpose through the MedCHAMPS project [6,7]. Based
on a Markov modelling approach [8], this model assumes
that the population can be divided into several pools at an
initial point of time defined as “starting states”: healthy
people (e.g. non-obese, non-smokers, and have no dia-
betes), people who are obese, and people who are smokers.
A proportion of the population moves from each starting
state to the diabetes state after each cycle lasting 1 year
and finally to two “absorbing states” that take into account
competing risk for mortality (diabetes-related deaths and
non-diabetes-related deaths) (Figure 1). Potential overlaps
between healthy, obese and smoking groups have been
taken into account by estimating conditional probabilities
of group membership. Furthermore, the model assumes
that there is no “remission” of people in the diabetes state
towards the previous states.
Demographic and risk factors trends in the population
are used to inform the relative size of the “starting states”
and its change over time. Transition probabilities are used
to estimate the proportion of persons moving from the
starting states to the diabetes or death states. (Additional
file 1: Table S4).
Data sets and estimation of key model parameters
The population structure at the baseline year (2003) was
obtained from the Syrian Bureau of Statistics [9]. For sub-
sequent years, population trends were obtained from the
United Nations Department of Economic and Social
Affairs [10], which predicts an almost doubling of the
Syrian population between 2003 and 2022. The increase
during this period is expected to be smallest for the youn-
gest age group (25–34 years), and highest for the age
group of 55–64 years. The age group of 75 years and over
is projected to have more women than men, although the
overall number of men is projected to be slightly higher
than women.
The prevalence of diabetes, obesity and smoking at the
baseline year were obtained from the STEPwise survey
(2003) in Syria [11]. In this nationwide survey involving
9184 participants, diabetes was defined as self-reported
diabetes multiplied by 1.5 to account for undiagnosed
cases [2]. Obesity was defined as having a body mass
index (BMI) higher or equal to 30. Smoking was defined
as current daily cigarette smoking. Obesity trends were
roughly estimated by extrapolation from local unpub-
lished data, whereby obesity prevalence was estimated to
have increased by 1% per year for all age groups except
for the 25–35 years age group, where the increase was
estimated to be at 0.2% per year. The obesity increase
was assumed to peak at 80% prevalence [12,13]. Smoking
trends were determined based on experts’ interviews
conducted by the MedCHAMPS project, in which a no-
change scenario was used. The baseline prevalences of
DM, obesity and smoking in 2003 were: 9.2% in men and
14.7% in women for diabetes, 29% in men and 40.1% in
women for obesity, and 59.1% in men and 18.8% in
women for smoking. Total mortality was obtained from
the United Nations Department of economic and social af-
fairs [10].
The population incidence of diabetes and diabetes-
related excess mortality were estimated using DisMod II
software [14,15], and were used to estimate key transition
Figure 1 The MEDCHAMPS IMPACT Diabetes model structure.
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probabilities. DisMod II can provide estimates of case fa-
tality and incidence for a disease if prevalence, remission
rate, and total and disease specific mortality rates are
known. For this study, we used diabetes prevalence in
2003, diabetes remission rate (which can be reasonably as-
sumed to be 0), and relative risk (RR) of mortality from
diabetes in 2003 for the Syrian population. The latter par-
ameter was estimated as proposed by Barendregt et al.
[16], based on diabetes prevalence in 2003 and usual RR
for mortality (mortality in diseased/mortality in non-
diseased) obtained from the Verona study [17]. The RR of
diabetes in obese and smoking individuals were obtained
from two recent systematic reviews and meta-analysis
[18,19]. The data used for this study is openly available.
More details on the data and on the calculation of the in-
cidence parameter are available in the technical appendix
(Additional file 1).
Comparison with the projections of international diabetes
federation (IDF)
The IDF estimated future diabetes prevalence among
people 20–79 years of age, while age range in the model
output for this study was 25 years and over. Therefore, to
allow better comparison with IDF estimates, prevalence of
diabetes was recalculated from the model outputs after ex-
cluding all people >79 years of age, and adding number of
people 20–24 years of age for each year assuming an ex-
tremely low prevalence of T2DM in this age band.
Estimating the potential gains of public health
interventions to prevent T2DM
To assess the potential effect of a likely successful policy
for diabetes prevention, the model was re-run after a
scenario of a hypothetical 10-year intervention program
(started in 2003) was included. The hypothetical preven-
tion program was assumed to target a group of non-
diabetic persons (10% of healthy, 40% of obese, and 20%
of smokers) for an expected reduction of 25% of obesity
and 50% of smoking in 10 years.
Results
Diabetes incidence, case fatality and mortality
According to the DisMod II outputs, the estimated an-
nual diabetes incidence was higher in women than in
men (1570 per 100,000 vs. 1190 per 100,000). The same
was found for diabetes-related mortality rate (70 per
100,000 in women vs. 50 per 100,000 in men). The rates
showed an increasing trend with age for both diabetes
Table 1 Projected prevalence and number of people with type 2 diabetes for selected years among adults 25 years of
age and over in Syria
2003 2006 2011 2022
Men 25-34 16995 (1.2) 37073 (2.2) 87962 (4) 249919 (11.3)
35-44 28483 (3.2) 57424 (5.4) 119992 (8.6) 325066 (15.7)
45-54 66424 (12.2) 91985 (14.3) 146472 (17.4) 329564 (23.9)
55-64 82300 (27) 95620 (27.2) 126473 (26.7) 245785 (30.5)
65-74 47502 (27) 56226 (28.8) 73564 (31.5) 129752 (33.3)
75+ 20797 (27) 24638 (28) 32497 (30.9) 52998 (37)
total 262500 (7.7) 362966 (9) 586960 (11.2) 1333084 (19)
Women 25-34 6682 (0.5) 26976 (1.6) 77663 (3.7) 231184 (10.9)
35-44 29348 (3.3) 63648 (6.1) 139289 (10.2) 388171 (19.8)
45-54 125064 (22.4) 151993 (23.1) 212463 (25.3) 419033 (32.1)
55-64 134372 (42.3) 148746 (40.7) 185811 (37.7) 322827 (40.7)
65-74 87573 (42.3) 97922 (43.1) 117106 (44.6) 167225 (38.9)
75+ 40655 (42.3) 43758 (38.9) 54410 (37.9) 83289 (41)
total 423694 (12.2) 533044 (13.1) 786742 (15.1) 1611729 (23.6)
Total 25-34 23678 (0.8) 64049 (1.9) 165624 (3.9) 481102 (11.1)
35-44 57831 (3.2) 121072 (5.7) 259281 (9.4) 713236 (17.7)
45-54 191488 (17.3) 243978 (18.7) 358935 (21.3) 748597 (27.9)
55-64 216672 (34.8) 244366 (34) 312284 (32.3) 568612 (35.6)
65-74 135075 (35.3) 154148 (36.5) 190670 (38.5) 296977 (36.2)
75+ 61452 (35.5) 68396 (34.1) 86908 (34.9) 136287 (39.3)
total 686195 (10) 896010 (11) 1373702 (13.1) 2944813 (21.3)
Data is shown as number and prevalence (%).
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incidence (from 405 per 100,000 in the 25–34 year age
group to 5085 per 100,000 in the ≥75 year age group),
and diabetes mortality rate (from 0 to 1120 per 100,000
in the 25–34 year and the ≥75 year age groups, respect-
ively). (Additional file 1: Table S4)
Projected prevalence of diabetes
Overall, the model predicts a relative increase of 113.8% in
diabetes prevalence (from10% to 21.3%), and of 329.2% in
number of people with diabetes (from 686,195 to
2,944,813) between 2003 and 2022. (Table 1 and Figure 2)
In women, the prevalence of and number of patients with
diabetes are estimated to be 12.2% (423,694) in 2003 and
23.6% (1,611,729) in 2022. In men, the numbers are lower;
7.7% (262,500) in 2003 and 19% (1,333,084) in 2022. How-
ever, the relative increase in the prevalence of diabetes and
number of diabetic people is higher in men than in
women (148.2% and 407.8% in men vs. 93.2% and 280.4%
in women) during the same period. Most of the increase
in the prevalence of diabetes is projected to occur in youn-
ger age groups, where diabetes is estimated to increase by
12.2 and 4.4 folds among the age groups of 25–34 years
and 35–44 years, respectively, as opposed to almost zero
increase in the age group of 55–64 years and above
(Table 1 and Figure 3). Among people 20–79 years of age,
and between 2011 and 2022, the model predicts a relative
increase of 69.4% in diabetes prevalence (from 10.9% to
18.4%), and of 115% in number of people with diabetes
(from 1,357,454 to 2,918,314) (Table 2).
If the scenario of 10-years prevention program de-
scribed above is initiated, the model predicts a small but
useful reduction in diabetes prevalence and diabetics
after 5 years, from 11.3% (977,938) to 11.1% (975,881).
More notable changes in diabetes prevalence and
diabetics as a result of the intervention are predicted to
occur later, with a reduction from 13.8% (1,488,379) to
12.6% (1,362,617) after 10 years, and from 21.3%
(2,944,813) to 16.4% (2,267,905) after 20 years (Figure 4).
Discussion
This is the first modelling study forecasting diabetes
prevalence in Syria using primarily local data. Starting in
2003, our model predicted that the number of individ-
uals with diabetes would increase four folds, and dia-
betes prevalence would double in about 20 years.
The IDF projections predicted a relative increase of
14.6% (from 8.2% to 9.4%) in diabetes prevalence, and
91.9% (from 889,500 to 1,706,700) in the number of dia-
betics among Syrian adults 20–79 years of age between
2011 and 2030 [2]. These estimates are substantially
lower than ours. Only between 2011 and 2022, our
model predicted a higher increase of 69.4% in diabetes
prevalence and of 115% in number of diabetics (Table 2).
These differences may be due to the absence of local
data inputs in the IDF projections. The IDF prevalence
estimates were therefore generated using an average of
available data from countries matched by IDF region,
World Bank’s income classification group, geography,
and ethnicity [20]. Another reason for this discrepancy
could be due to diabetes-related mortality estimates.
Deaths attributed to diabetes in Syria were estimated by
the IDF at 6,066 in 2011, while a lower estimate (4,841)
of diabetes mortality for the same year was found in our
study using the DisMod II model.
Our results suggest that the increase in diabetes preva-
lence and number of diabetics in Syria will be substan-
tially higher than in many other developing countries in
the Middle Eastern and North African regions [3]. Our
Figure 2 Projected trend of type 2 diabetes mellitus prevalence in Syria from 2003 to 2022, by gender.
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Figure 3 The relative increase in prevalence of type 2 diabetes mellitus between 2003 and 2022 among Syrian adults stratified by age.
Table 2 Projected prevalence and number of people with type 2 diabetes for selected years among adults 20–79 years
of age in Syria
2003 2006 2011 2022
Men 20-24* 0 (0) 0 (0) 0 (0) 0 (0)
25-34 16995 (1.2) 37073 (2.2) 87962 (4) 249919 (11.3)
35-44 28483 (3.2) 57424 (5.4) 119992 (8.6) 325066 (15.7)
45-54 66424 (12.2) 91985 (14.3) 146472 (17.4) 329564 (23.9)
55-64 82300 (27) 95620 (27.2) 126473 (26.7) 245785 (30.5)
65-74 47502 (27) 56226 (28.8) 73564 (31.5) 129752 (33.3)
75-79 10398 (27) 12319 (28) 16249 (30.9) 26499 (37)
total 252102 (6.2) 350647 (7.2) 570712 (9.1) 1306585 (16.2)
Women 20-24* 0 (0) 0 (0) 0 (0) 0 (0)
25-34 6682 (0.5) 26976 (1.6) 77663 (3.7) 231184 (10.9)
35-44 29348 (3.3) 63648 (6.1) 139289 (10.2) 388171 (19.8)
45-54 125064 (22.4) 151993 (23.1) 212463 (25.3) 419033 (32.1)
55-64 134372 (42.3) 148746 (40.7) 185811 (37.7) 322827 (40.7)
65-74 87573 (42.3) 97922 (43.1) 117106 (44.6) 167225 (38.9)
75-79 40655 (84.6) 43758 (77.8) 54410 (75.8) 83289 (82)
total 423694 (10.3) 533044 (11) 786742 (12.7) 1611729 (20.7)
Total 20-24* 0 (0) 0 (0) 0 (0) 0 (0)
25-34 23678 (0.8) 64049 (1.9) 165624 (3.9) 481102 (11.1)
35-44 57831 (3.2) 121072 (5.7) 259281 (9.4) 713236 (17.7)
45-54 191488 (17.3) 243978 (18.7) 358935 (21.3) 748597 (27.9)
55-64 216672 (34.8) 244366 (34) 312284 (32.3) 568612 (35.6)
65-74 135075 (35.3) 154148 (36.5) 190670 (38.5) 296977 (36.2)
75-79 51053 (58.9) 56077 (55.9) 70659 (56.8) 109788 (63.4)
total 675796 (8.2) 883691 (9.1) 1357454 (10.9) 2918314 (18.4)
Data is shown as number and prevalence (%). * This young age group was assumed to have no cases of type 2 diabetes mellitus.
Al Ali et al. BMC Public Health 2013, 13:507 Page 5 of 7
http://www.biomedcentral.com/1471-2458/13/507
projections are also higher than those reported for devel-
oped countries. For example, the IDF projected an in-
crease in prevalence of diabetes from 10.9 in 2011 to
11.8% in 2030 in the United States, from 7.3% to 8.8% in
the Netherlands, and from 6.8% to 7.5% in the United
Kingdom [2].
Interestingly, our results predict that the increase in
diabetes prevalence and number of individuals with dia-
betes will be higher in younger age groups (< 55 years),
especially for women (Figure 3). This is consistent with
the literature predicting an increase in diabetes risks in
younger adults in non-western societies [21]. Therefore,
a special emphasis in any efforts to reduce diabetes bur-
den in the Syrian and similar societies should be directed
towards these age groups.
Another interesting population trend in diabetes is re-
lated to the urban–rural distribution. For example, in de-
veloped countries the prevalence of diabetes is reported to
be similar in rural and urban areas [22]. For most develop-
ing countries however, the prevalence of diabetes in rural
areas is assumed to be one-half that of urban areas [23].
The model used in this study did not make assumptions
and projections regarding diabetes prevalence in rural vs.
urban regions. However, a recent study from Syria esti-
mated the prevalence of diabetes among urban popula-
tion ≥ 25 years of age (2006) to be at 15.6% [24]. In this
report, the model-estimated prevalence of diabetes in the
total population in 2006 is 11%. Assuming roughly equal
distribution of the Syrian population between rural and
urban areas [9], the prevalence of diabetes among rural
populations in Syria is likely to be substantially lower than
that of urban areas (approximately 6.5%). This suggests
that the pattern of diabetes distribution in Syria is similar
to that in other developing countries, and a prominent
role for urban lifestyles in diabetes morbidity.
Our intervention modelling shows that an important
impact on diabetes prevalence could be achieved if an
intervention program was implemented in 2003 to re-
duce the levels of obesity (by 25%) and smoking (by
50%) within 10 years. Although such reductions in obes-
ity and smoking are hard to achieve in practice, the
resulting reduction of 23% in diabetes prevalence by
2022 (a reduction of more than half a million diabetes
cases) provides policy makers with some reliable bench-
marks to gauge the size and impact of any planned inter-
vention to reduce diabetes in the Syrian society.
Clearly, both IDF and the current study have methodo-
logical limitations. Our diabetes prevalence forecasting
was based on trends in obesity and smoking, but did not
include any other risk factors such as physical activity. No
data on obesity and smoking trends is available in Syria.
Therefore, the obesity trends used in this study were as-
sumed based on cross sectional data combined with a
rough extrapolation of local unpublished data consistent
with the global increasing trend in obesity levels [25]. On
the other hand, smoking trends were assumed to be steady
in each age group for both genders. Moreover, the data
from the STEPwise survey in Syria (2003) were not strati-
fied by urban and rural status, precluding us to model this
important factor. Finally, no diabetes projections could be
obtained for the 20–24 year age group because no data on
diabetes for this age group exist for Syria. This has
prevented us from conducting a more robust comparison
with IDF projections, which included people 20–79 years
of age. However, the inclusion of this age group in our
model output with the assumption of very low prevalence
Figure 4 Predicted effect of a hypothetical 10-years prevention program (starting in 2003) on prevalence of type 2 diabetes mellitus.
The hypothetical prevention program used here is assumed to target a group of non-diabetic persons (10% of healthy, 40% of obese, and 20% of
smoker) with an expected reduction of 25% of obesity and 50% of smoking in 10 years.
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of diabetes along with the exclusion of people > 79 years of
age allowed for some valid comparisons to be made be-
tween our and IDF’s projections.
Conclusions
This study provides the first future projections of diabetes
in Syria based on national data and epidemiological mod-
elling techniques. Our data show that the burden of dia-
betes in Syria will markedly increase in the future
potentially putting Syria amongst the top ten countries in
diabetes prevalence worldwide. It also shows that our
projected increases in diabetes burden surpass those of
the IDF, highlighting the importance of local data in
informing future projections. Available interventions can
thwart this bleak forecast, but they will require extensive
and sustained efforts targeting obesity and smoking in the
Syrian society.
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